About: Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article by Brian I Rini et al published 15 February 2011 in Cancer

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 2011 (uk) im Februar 2011 veröffentlichter wissenschaftlicher Artikel (de) article by Brian I Rini et al published 15 February 2011 in Cancer (en)
publication date	wds:Q56899094-810D1AD7-BAE2-4138-8723-6A82DAF61B4E
publication date	2011-02-15 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q56899094-BA4DC463-BCB1-4C92-A13F-4A33444B70DC
language of work or name	English
cites work	wds:Q56899094-20F83F85-3CA6-43B8-99F2-55DDBA087308 wds:Q56899094-36AEC087-684A-4146-8BD1-452A1A2CF5B0 wds:Q56899094-3B95735D-8EE0-4983-BC2B-FDCC1882A626 wds:Q56899094-47E64663-A064-4B15-B1E2-4B26056DE02A wds:Q56899094-694E63F3-2FC0-40FD-83F6-F089D7D06B0D wds:Q56899094-AB780149-1A8B-4EE7-B28F-B042CC88F476 wds:Q56899094-BC0FFBAF-76B6-45A5-A746-3F88A48B3C9D wds:Q56899094-CF9E27D8-29DD-4244-A025-3B3468F15C88 wds:Q56899094-EDC4F3A8-D10D-4A59-90BF-135E88BDB849 wds:Q56899094-FFEB7B21-8241-4A21-8EFC-37972992D3D5
cites work	Phase I/II trial of tremelimumab in patients with metastatic melanoma Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells Recent progress in the management of advanced renal cell carcinoma Sunitinib versus interferon alfa in metastatic renal-cell carcinoma Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma Metastatic renal cell carcinoma: current standards of care
author name string	wds:Q56899094-00BB069F-69F8-40EF-8392-50FC1161F401 wds:Q56899094-07D42E11-542C-4DB2-847E-0C72E58E0B56 wds:Q56899094-1A3753C5-D370-465B-8BBF-A5FCC723A3BC wds:Q56899094-2F48C0C4-BC73-4D3B-B4C0-565C8DE09DCC wds:Q56899094-4FAEA20F-1F8A-4D58-BA84-B8C6E73FF6AE wds:Q56899094-D780467F-21D8-470F-854D-6ACB4534C657 wds:Q56899094-F64F445F-2E33-4254-BD56-3F6202552960 wds:Q56899094-FB42DD3E-C52A-4C75-BEDE-8FA60753E796 wds:Q56899094-FD0C3BED-1101-4349-8CA5-A7BC04801E74 wds:Q56899094-FD25EB82-A301-4849-8700-FED0F9B2AC03
author name string	Michael Gordon Allison Tyler Bo Huang Brian I Rini Joe J Stephenson Mark Stein Simantini Eddy Diane Healey Pat Shannon Lorie Catlett
rdfs:label	Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma (en) Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma (nl)
skos:prefLabel	Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma (en) Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma (nl)
name	Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma (en) Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma (nl)
title	wds:Q56899094-45FAB973-9EDF-49E3-BCB2-5F1A7B6F205D
title	Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma (en)
page(s)	wds:Q56899094-7B0F7786-17F0-4DA1-B06D-6025B9DF0469
page(s)	758-67
instance of	wds:Q56899094-EBDA8579-1215-46AA-96D1-992098FE6B30
instance of	scholarly article
main subject	wds:Q56899094-00F56B1B-9FD4-46EB-9C14-09E09A2A7D2C wds:Q56899094-424BF362-E0F0-4BD7-A71F-0E618DC02660 wds:Q56899094-B7BECBFF-36A4-444B-B3C4-FEA059E3FDCF wds:Q56899094-EA1BF134-8ED8-4B76-A37F-93B90CFA3EB1
main subject	phase I clinical trial Patients renal cell carcinoma metastatic renal cell carcinoma
PubMed ID	wds:Q56899094-A0371A01-AB69-4346-B6B4-5E4C6B8D1943
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/20922784
PubMed ID	20922784
published in	wds:Q56899094-BC044A8B-E3EA-42D9-AD77-82655473E17E
published in	Cancer
issue	wds:Q56899094-DACCC133-D4C4-4C14-A8F9-205A70727C28
volume	wds:Q56899094-8FD3BD79-21B7-419A-B468-F99B6694C999
issue	4
volume	117
DOI	wds:Q56899094-BDCB3388-5939-4970-80EA-E7D30B52079E
DOI	http://dx.doi.org/10.1002/CNCR.25639
DOI	10.1002/CNCR.25639
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q56899094
is cites work of	Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours Immune Checkpoint Blockade in Cancer Therapy PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence Immune modulation in cancer with antibodies Role of immunotherapy for renal cell cancer in 2011 PD-1 as a potential target in cancer therapy Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review Combination cancer immunotherapy and new immunomodulatory targets Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody Targeting costimulatory molecules to improve antitumor immunity. Modulation of CTLA-4 and GITR for cancer immunotherapy Trial Watch: Monoclonal antibodies in cancer therapy Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma Emerging immunotherapies for renal cell carcinoma Dendritic cell-based vaccines: clinical applications in breast cancer. Tremelimumab: a review of development to date in solid tumors Tremelimumab: research and clinical development

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software